Clinical Trial Results:
A phase IIa single-centre, randomised, double-blind, placebo-controlled, two-way cross-over allergen challenge study to evaluate the effect of treatment with once daily AQX-1125 on the late asthmatic response (LAR) to Inhaled Allergen Challenge (IAC) in subjects with mild to moderate atopic asthma.
Summary
|
|
EudraCT number |
2011-003012-23 |
Trial protocol |
GB |
Global completion date |
13 Apr 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Nov 2018
|
First version publication date |
09 Nov 2018
|
Other versions |
|
Summary report(s) |
AQX-1125-200_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.